Uridine triacetate: the saviour in waiting, finally arrives


  • Shruti Jaiswal Department of Pharmacology, PESU Institute of Medical Sciences and Research, Konappana Agrahara, Electronic City, Bengaluru, Karnataka, India




Toxicity, 5-FU, Capecitabine, Uridine triacetate


Cancer of the gastrointestinal tract is one of the very common solid cancers. Colorectal cancer is one of the types in which the anticancer drug 5-fluorouracil (5-FU) or its prodrug capecitabine is used. Toxicity to 5-FU or capecitabine is a common occurrence in patients receiving it. In such conditions, dose reduction or drug discontinuation for some time was the only way out apart from some supportive measures. An exhaustive search was always on to find a suitable antidote for the toxicity. The molecule uridine triacetate was studied for a long to be used in this condition. A systematic search of the existing literature about uridine triacetate was done with available sources like PubMed, Google Scholar, etc. Information about uridine triacetate was assembled and processed from these sources. Uridine triacetate was given orphan drug status for this indication a few years back. After a clinical trial, the drug was finally approved by the US FDA on December 11, 2015, for use in case of toxicity to 5- 5-FU or capecitabine. Well, stat Therapeutics has been marketing the drug under the trade name of Vistogard. Uridine triacetate works by preventing the toxic metabolite of 5-FU from entering and establishing itself in the RNA framework, by competing with the toxic metabolites. It is a relatively safe drug with minimal side effects. This article discusses the molecule uridine triacetate, its structure, metabolism, and kinetics in the body, the why and how of its action, and finally the results and findings of the clinical trial done with it.


Hofheinz RD, Heinemann V, von Weikersthal LF, Laubender RP, Gencer D, Burkholder I et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer. 2012;107(10):1678-83.

Renck D, Machado P, Souto AA, Rosado LA, Erig T, Campos MM et al. Design of Novel Potent Inhibitors of Human Uridine Phosphorylase-1: Synthesis, Inhibition Studies, Thermodynamics, and in Vitro Influence on 5-Fluorouracil Cytotoxicity. J Med Chem. 2013;56(21):8892-902.

McIntyre WJ, Downs MR, Bedwell SA. Treatment Options for Actinic Keratoses. Am Fam Physician. 2007;76(5):667-71.

Lucena SR, Salazar N, Gracia-Cazaña T, Zamarrón A, González S, Juarranz Á et al. Combined Treatments with Photodynamic Therapy for Non-Melanoma Skin Cancer. Int J Mol Sci. 2015;16(10):25912-33.

Simonova AY, Ponomarev IN, Makarov IV, Teterin YS, Borovkova NV, Mironov AV et al. 41st International Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) 25-28 May 2021, Virtual Meeting. Clinical Toxicol. 2021;59(6):537-602.

Al Safarjalani ON, Rais R, Shi J, Schinazi RF, Naguib FN, El Kouni MH. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5- (Phenylthio)acyclouridine, a uridine phosphorylase inhibitor. Cancer Chemother Pharmacol. 2006;58(5):692-8.

Young JS, Simmons JW. Chemotherapeutic Medications and Their Emergent Complications. Emerg Med Clin North Am. 2014;32(3):563-78.

Livshits Z, Rao RB, Smith SW. An Approach to Chemotherapy Associated Toxicity. Emerg Med Clin North Am 2014;32:167–203

Reigner B, Blesch K, Weidekamm E. Clinical Pharmacokinetics of Capecitabine. Clin Pharmacokinet. 2001;40(2):85-104.

The New York State Poison Centers TOXICOLOGY LETTER. Vistonuridine®: A Novel Antidote for 5-fluorouracil. 2010. Available at: http://www.upstate.edu/poison/pdf/tox_newsletter/01_10toxnews.pdf. Accessed on 20 December, 2023.

White J, Hu P, Bonen M, Bamat MK, Borstel RV. Point-of-care (POC) diagnostic assay for 5-fluorouracil (5-FU) quantitation to enable dose adjustment and detect dihydropyrimidine dehydrogenase (DPD) deficiency. J Clin Oncol. 2011;29(15):e19562.

Institute for Safe Medication Practices. Fluorouracil error ends tragically, but the application of lessons learned will save lives. 2007. Available at: https://www.ismp.org/newsletters/acutecare/articles/20070920.asp. Accessed on 25 September, 2023.

McEvilly M, Popelas C, Tremmel B. Use of uridine triacetate for the management of fluorouracil overdose. Am J Health Syst Pharm. 2011;68:1806-9.

Pinzani V. Capecitabine and 5-FU overdoses. Potential interest of the

antidote: Vistonuridine? Fundamental Clin Pharmacol. 2013;27:106.

Fda.gov.vistogard. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208159s000lbl.pdf. Accessed on 22 September. 2023.

Orotic aciduria type 1. Available at: https://rarediseases.info.nih.gov/gard/5429/orotic-aciduria-type-1/resources/1. Accessed on 25 December, 2023.

Grohmann K, Lauffer H, Lauenstein P, Hoffmann GF, Seidlitz G. Hereditary Orotic Aciduria with Epilepsy and without Megaloblastic Anemia. Neuropediatr. 2015;46(2):123-5.

Search Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=401013. Accessed on 25 December, 2023.

Search Orphan Drug Designations and Approvals. Available at: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=273808. Accessed on 25 December, 2023.

Drugs@FDA: FDA Approved Drug Products. Available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails. Accessed on 25 December, 2023.

Peters GJ, van Groeningen CJ. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol. 1991;2(7):469-80.

Seiter K, Kemeny N, Martin D, Schneider A, Williams L, Colofiore J et al. Uridine Allows Dose Escalation of 5-Fluorouracil When Given with N-Phosphonacetyl-L-Aspartate, Methotrexate, and Leucovorin. Cancer. 1993;71(5):1875-81.




How to Cite

Jaiswal, S. (2024). Uridine triacetate: the saviour in waiting, finally arrives. International Journal of Basic & Clinical Pharmacology, 13(2), 283–288. https://doi.org/10.18203/2319-2003.ijbcp20240388



Review Articles